Up to 80% of women who have signs of premature labour – like contractions or pain in their belly – are still pregnant after 7 days. However, it is very difficult to tell which of these women are actually at risk of premature birth. A lot of women are treated ‘just in case,’ as doing nothing could have devastating consequences.
A test called quantitative fetal fibronectin (fFN) could help change this.
Fetal fibronectin is a special protein made by babies’ cells in the womb, and acts as a 'glue' that keeps the amniotic sac attached to the lining of the womb.
The protein can be tested by taking a swab, which is analyzed to give results in less than ten minutes. The lower the concentration of fFN, the less likely a woman is to give birth early.
A test that simply gives a positive or negative result has been available for a while. However, this new test could rule out preterm labour more accurately than ever. In work funded by the National Institute for Health Research, Tommy’s researchers will look at earlier studies to find out if quantitative fFN is likely to be useful. They will also look at which other clinical factors could be used together with the test to best diagnose premature labour.
We will try and use the test to predict if a woman will deliver within seven days at eight maternity units in the UK. Using our results, we’ll develop a support tool to help women and clinicians decide how likely premature birth is, and whether a woman should start treatment.
If it works, this tool could help stop women who aren’t at risk being unnecessarily admitted to hospital. This means we can focus care on those women who need it most, and avoid stress, worry, and treatment for those who don’t.
Sarah Stock, Jane Norman, Andrew Shennan, John Norrie Kathleen Boyd, Ben Mol Susan Harper-Clarke, Irene Brady, Tina Lavender, Khalid Khan, Rachel Morris, Manju Chandiramani, Asma Khalil, Lesley Jackson, Jon Dorling, Richard RileyHide details
This study takes place in a Tommy's centre and is funded by the National Institute for Health Research's Health Technology Assessment programmeHide details